"The Senators will finance Cloning Blood !!!!!", saysChairman Natto.
Testimony by George Q. Daley, MD, PhD
Appropriations Subcommittee on Labor, Health and Human Services, Education
Hearing on “An Alternative Method for Obtaining Embryonic Stem Cells”
July 12, 2005
Senator Specter, members of the Committee, thank you for inviting me to testify before you. My name is George
Daley. I am here today representing the American Society for Cell Biology, a professional society of nearly 12,000 basic biomedical
researchers in the United States and 50 nations around the world.I am Associate Professor of Pediatrics
and Biological Chemistry at Boston Children’s Hospital and Harvard Medical School, the Associate Director of the Stem
Cell Program at Children’s Hospital, a member of the Executive Committee of the Harvard Stem Cell Institute, and Board
Member and President-elect of the International Society
for Stem Cell Research (term to begin June 2007). My research is focused on using embryonic stem cells and adult stem cells
to study blood development, and to develop new treatments for leukemia, and genetic diseases like immune deficiency, sickle
cell anemia, thalassemia, and Fanconi’s anemia. I am also clinically active as a hematologist at Children’s Hospital,
where I see first-hand the pain and suffering inflicted by these diseases on children and their families. My career is dedicated
to making a difference in their lives through research and patient care.
I am here today to state my strong support for Senate passage of HR 810, which has already passed the House of
Representatives by an impressive and bipartisan margin. HR 810 would ensure that scientists can use Federal grant funds to
study the wide range of valuable human embryonic stem cell lines that have been created since August 9, 2001, the date that President Bush announced his restrictive
stem cell research policy. HR 810 would expand research opportunities and accelerate progress towards newer and better therapies
for the many children I currently cannot treat successfully.
I am also here to give scientific perspective on the several additional strategies proposed for deriving human
pluripotent stem cells that have been considered recently by the President’s Council on Bioethics, and which are the
subject of this hearing today. I want to state at the outset that I support efforts to derive pluripotent stem cells by methods
that would be ethically acceptable to all, but I do not support delaying the pursuit of medical research on existing human
embryonic stem cell lines while these more speculative methods are tested. I believe that Senate passage of HR 810 is the
surest means of supporting stem cell research at this juncture.
First let me emphasize why research on human embryonic stem cells is so vitally important, and why alternative
forms of adult stem cell research cannot substitute for the study of embryonic stem cells.
Critics of embryonic stem cell research are fond of saying that adult stem cells have been used to cure
dozens of diseases while embryonic stem cells have helped no one. I would like to examine that claim. In essentially all cases
adult stem cell therapy really means transplantation of blood stem cells to treat leukemia, lymphoma, and various genetic
diseases of the blood. Although bone marrow transplants have saved many lives, bone marrow transplant is never a certain cure.
Even after many decades of clinical experience, bone marrow transplant remains an aggressive and toxic therapy that carries
the highest mortality rate of any medical procedure that is routinely performed. For patients whose only bone marrow match
is from unrelated donors outside the family, the treatment itself claims the lives of ~30% of patients in the first year.
Indeed, I have cared for many patients who have died during treatment. All of us working in hematology today agree that additional
research is needed.
My laboratory is studying embryonic stem cells in hopes of making blood stem cell transplants safer and
more widely applicable. A critical part of the strategy is using somatic cell nuclear transfer to generate stem cells that
are customized to the specific patients I mentioned earlier, kids with leukemia, immune deficiency, and sickle cell anemia.
We hope to correct the genetic defects in these patient-specific cells, direct their differentiation into blood, and transplant
kids with these genetically matched autologous cells. This strategy is already working in mice, and we are eager to translate
this work into humans. The current Federal funding policies have held us back.
Although it is true that no one has to date been treated with cellular therapies based on human embryonic
stem cells, I can assure you that mouse embryonic stem cells have had a major impact on medical research. Over the past 25
years, mouse embryonic stem cells have been used to create models for scores of human diseases, including cancer, heart disease,
obesity, and Alzheimer’s. Research discoveries based on these models has led to new drug development and therefore touched
countless lives. As for the criticism that no one has been cured with embryonic stem cells, the field of human embryonic stem
cell research is a mere 7 years old, so it is premature to expect successful cell therapies to have already been delivered
to patients. I believe it is only a matter of time before human embryonic stem cells are used in drug development research
and become the basis for important new cell therapies.
As further evidence of how human embryonic stem cells enable unique opportunities to study disease, consider
research on Fanconi’s anemia. Kids with Fanconi’s anemia suffer bone marrow failure, and often develop leukemia.
Scientists have tried to model this disease in mice, but the mice do not develop bone marrow failure, and the adult blood
stem cells from Fanconi’s patients cannot be maintained in culture. Recently, a team from the Reproductive Genetics
Institute of Chicago isolated a human embryonic stem cell line that carries a Fanconi’s gene mutation. This cell line
could enable us to study the uniquely human aspects of Fanconi’s anemia. However, because of the current Presidential
policy, we cannot study these cells with our Federal grant dollars. Thus my lab has been left to attempt to generate a Fanconi’s
model in one of our Presidential stem cell lines, which has proven to be far more cumbersome than simply obtaining the cells
from Chicago. To date, we have not succeeded. By this
direct example, the President’s policy is hindering our research on this terrible childhood disease. Senate passage
of HR 810 would make available Federal funds to perform this important medical research. [I have written about the “missed
opportunities” for human embryonic stem cell research under the current Presidential policies, and wish to introduce
this article into the record1.]
Let me now turn to the several proposed new methods for making pluripotent human stem cells that are designed
to avoid the destruction of a human embryo. These so-called “alternatives” are not TRUE alternatives, as they
currently represent only speculative proposals for research that might yield new stem cell lines, and are fraught with their
own ethical problems. In most of these cases, the experiments needed to establish feasibility of these proposals would require
research on human embryos, and thus would be prohibited under current Federal law by the Dickey amendment. Far preferable to spending limited research dollars on these speculative proposals, in my opinion, is support for research
on additional embryonic stem cell lines that are available today—lines that are similar to those already approved under
the Bush policy. Senate passage of HR 810 would advance research that we know works, research where the ethical dilemmas
have been understood and accepted by most.
Among the speculative methods under discussion, the first involves extracting stem cells from embryos that could
be considered “dead”, because they have stopped dividing and will not develop further. If individual cells remain
alive (and hopefully normal), they might be used to initiate lines of stem cells. The President’s Council found this
strategy ethically sound and scientifically feasible and so endorsed it. However, I anticipate that attempts to generate pluripotent
cells from these defective embryos will be far less efficient than from excess IVF embryos. Even if cell lines can be generated,
I imagine scientists will remain suspicious that they are abnormal and might lead to erroneous conclusions in research.
The second speculative method derives from pre-implantation genetic diagnosis, or PGD, in which one or two cells
are removed from an early embryo and analyzed to diagnose serious inherited diseases like Sickle Cell Anemia. PGD insures
that only embryos found free of gene defects are transferred to the woman so that she may have a healthy child. The suggestion
has been made that biopsied cells might be used to produce pluripotent stem cell lines, and this would be ethically acceptable
if the embryo remained unharmed. Dr. Lanza is here to represent his as yet unpublished success in using this strategy to produce
pluripotent stem cell lines from mouse embryos. However, the biopsy procedure raises all sorts of ethical concerns and indeed
has been dismissed as unacceptable during the initial inquiries of the President’s Council. [Those who equate the zygote
to a human being would reject the use of embryo biopsy because it removes cells at a stage when they might be considered developmentally
equivalent to the zygote—that is, totipotent. Removing a totipotent blastomere is then the moral equivalent of producing
a twin, which, in the view of opponents of embryonic stem cell research could not then be sacrificed for research. Embryo
biopsy for stem cell research entails risks to embryos that are wanted for making a baby, rather than destined to be discarded
as medical waste. If my wife and I carried a genetic disease we would accept the risk of the embryo biopsy procedure to insure
we could have the healthiest child possible, but if we were simply infertile and using IVF to assist us in reproduction, we
would not consent to having our healthy embryos biopsied; we would chose instead to donate our excess embryos to stem cell
research. Dr. Lanza may suggest that lines be derived only from embryos already being biopsied for PGD, but the more cells
one biopsies to accommodate both PGD and stem cell derivations, the greater the risk for embryo loss. As a practical and scientific
matter, embryo biopsy for derivation of pluripotent cell lines is an unacceptable option.]
The third speculative method involves deriving pluripotent stem cells from something the President’s Council
has termed “biological artifacts”. The best described of this procedure is called “Altered Nuclear Transfer”,
which entails introducing a genetic defect into a somatic donor cell prior to nuclear transfer, so that a disordered embryo
results that can be a source of pluripotent stem cells but cannot develop into a human. According to Dr. Hurlbut, the method’s
chief proponent, what is produced would “lack the essential attributes and capacities of a human embryo”, a biological
artifact whose destruction to produce pluripotent stem cells would be ethically justified. Such a strategy is technically
feasible but in a piece written for the New England Journal of Medicine, my colleagues and I have rejected this concept as
flawed2. In reasoning echoed by the President’s Council, we questioned whether
the planned creation of what amounts to a defective embryo would silence ethical objections.
A more recent proposal put forth by Markus Grompe is a variation on Altered Nuclear Transfer called Oocyte Assisted
Reprogramming, (OAR). Grompe also suggests altering the input somatic cell so as to preclude formation of a viable human embryo.
He proposes using a gene like nanog, which might promote reprogramming of the donor somatic cell directly to something that
resembles an embryonic stem cell, which is pluripotent, and avoids generating a cell like a zygote, which is totipotent—that
is, able to divide on its own and form a viable human blastocyst. Scientifically, this idea is a reasonable hypothesis that
must be tested and might or might not work. But even if this strategy works in mice, there is no guarantee it will work in
humans, and verification would then require the creation and destruction of many manipulated human embryos, which might or
might not have the altered characteristics that would make this method ethically “acceptable”. If it works, I
am concerned that in order to use Federal dollars for research US Scientists will be relegated to less-efficient processes
like Altered Nuclear Transfer, while Korean scientists employ superior techniques.
The fourth speculative approach is to derive pluripotent cells via direct de-differentiation of somatic cells
to an embryonic stem cell-like state using chemical treatments or cell culture manipulation alone. The President’s Council
found merit in this fourth proposal, but also raised the technically thorny issue of how to rule out whether a totipotent
and therefore morally significant cell might be created by this procedure. In my view, these last two proposals raise a curious
and challenging question: can we distinguish the moral value of a human cell based on its particular gene expression pattern?
Can humanity really be diagnosed at the level of a single cell?
From my view, this last approach has scientific merit. We know cellular de-differentiation is possible; indeed,
that is precisely what we do when we perform somatic cell nuclear transfer and reprogram a somatic cell back to a zygote.
The Federal Government is already funding research into such cellular reprogramming. Indeed, last year I was one of nine recipients
of the inaugural Pioneer Award from the Director of the National Institutes of Health to support highly innovative (that is,
speculative) research of exactly this type. Although this strategy is worth pursuing, it is extremely high-risk, and may take
years to perfect, and may never work as well as nuclear transfer, which we know we can practice today.
Research on each of these proposed strategies is at present untested in human cells, but if judged to be meritorious
by the peer review process, should be funded. However, the already proven routes to obtaining embryonic stem cells from excess
IVF embryos or through the use of somatic cell nuclear transfer should not be put on hold pending the outcomes of the more
Finally, let me emphasize that research on embryonic stem cells and embryo research in general is not solely about
making tissues for transplantation to treat disease. Although the promise of new therapies is perhaps the most compelling
reason to support expanded access to embryonic stem cells for research, I stress that it is equally important to pursue research
that addresses fundamental questions about the earliest stages of human development. We know that a variety of birth defects
can be traced to abnormal cell divisions during the first few days of life, and that infertility and miscarriage can also
be traced to defects in the early embryo. We cannot learn everything there is to learn about these human disease conditions
from studying animals. We must study the unique aspects of human embryo biology directly, and the Federal government should
support this vitally important basic research.
Science certainly cannot define when in the gradual course of human development we deserve individual and autonomous
rights. I do not agree with the premise that the single celled zygote should be given the same considerations as living persons
and I do not view the embryo as a human being, particularly when it is frozen in a freezer. As a physician and as a scientist
and as a father I live in a practical world of choices, and a world in which disease is a grim reality. Unless we want to
turn back the clock, and outlaw in vitro fertilization, then we as a society have already accepted that many more embryos
are created than will ever become children. I feel it is morally justified to derive benefit from these embryos through medical
research instead of relegating them to medical waste. And unless we are willing to argue the biological absurdity that our
humanity can be defined by a particular signature of gene expression that exists in the totipotent cells of the early human
embryo, then we must support the vitally important applications of embryonic stem cells to medical research.
1.Daley, G.Q. Missed opportunities in embryonic stem-cell research. N Engl J Med351, 627-8 (2004).
2.Melton, D.A., Daley, G.Q. & Jennings, C.G. Altered nuclear transfer in stem-cell research - a flawed proposal.
N Engl J Med351, 2791-2 (2004).
Disclaimer of Warranty and Limitation of Liability The information,
products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.
The KIN Consortium does not warrant the information or services provided herein or your use of this
web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties,
including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose.
The KIN Consortium will not be responsible for any loss or damage that could result from interception
by third parties of any information or services made available to you via this web site. Although the information provided
to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium
cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available
to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors,
officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage
that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any
other party involved in making this web site, the data contained herein or the products or services offered on this web site
available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these
materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN
Consortium or of any vendor providing software or services. In no event will The KIN Consortium
or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental
damages or any other damages of any kind even if The KIN Consortium or any other such party has been
advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any
viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone
or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator
errors, strikes or other labor problems. The KIN Consortium cannot and does not guarantee continuous,
uninterrupted or secure access to the web site.
Proprietary Rights All right, title and interest
in this web site and any content contained herein is the exclusive property of The KIN Consortium ,
except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and
you may print, copy and download any information or portion of this web site for your personal use only. You may not modify,
copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer,
or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products
or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior
written approval. If you copy or download any information or software from this web site, you agree that you will not remove
or obscure any copyright or other notices or legends contained in any such information.
The KIN Consortium and
other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium .
The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks
of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags
on other pages or sites on the World Wide Web without the written permission of The KIN Consortium
or such third party, which may own the marks.
Pursuant to Section 512(c)(2) of the Copyright Act, The KIN
Consortium designates the following agent to receive notifications of claimed infringement: Khalid I Natto,
The KIN Consortium , Email: firstname.lastname@example.org Website: http://khalidnatto.tripod.com